All for Health
Health for All

China National Biotec Group Company Limited

China National Biotec Group Company Limited (CNBG) was first founded in 1919 as the Central Office of Epidemic Prevention. After the People’s Republic of China (PRC) was founded in 1949, it became administered by the Ministry of Public Health of the PRC. In 2010, the company was restructured as a subsidiary of China National Pharmaceutical Group Co., Ltd. (Sinopharm). At present, it has grown into a comprehensive biopharmaceutical company that integrates scientific research, production, sales, and postgraduate training. By the end of 2019, CNBG boasted 12 second-tier subsidiaries and 76 third- and lower-tier subsidiaries, with a total staff of 12,551 employees.


CNBG has diverse business segments covering six biopharmaceutical fields: human vaccines, blood products, medical aesthetics, animal health, antibodies and therapeutics, and medical diagnostics. It annually produces more than 700 million doses of 50 kinds of human vaccines, ranking the sixth in the world and supplying over 80 percent of vaccines for the National Immunization Program. With an annual plasma collection of more than 1,500 tons, CNBG produces 11 kinds of blood products. As the only botulinum toxin manufacturer approved by the Chinese government, CNBG’s own branded products are highly recognized by the medical aesthetics market. CNBG is also providing the society with all-round, high-quality services for animal vaccines and related veterinary biological products. It has developed a complete industrial chain for antibody drugs and a unique industrial chain for molecular diagnostic products.


Adhering to the philosophy of “All for Health, Health for All,” CNBG actively fulfills its social responsibility and has provided professional support for the country’s emergency responses to the outbreaks of major infectious diseases and epidemic prevention and control, as well as in disaster rescue and relief, which helped secure social stability. In the battle against the COVID-19 pandemic, CNBG has played an active role in scientific research, spearheading efforts from nucleic acid test kit development to the therapy of using plasma collected from recovered COVID-19 patients to treat the disease, and to obtaining certificate of approval for phase-3 clinical trials of an inactivated COVID-19 vaccine it developed. A series of major scientific research achievements have provided strong support for making the disease diagnosable, treatable and preventable.


Since the 13th Five-Year Plan began in 2016, CNBG has played a leading role in the industry and is striving to become a standard-setting innovative biopharmaceutical company with global competitiveness and respect.

  • 12
    second-tier subsidiaries
  • 76
    third- and lower-tier subsidiaries
  • 80%
    CNBG supplies over 80% of vaccines used in the National Immunization Program
  • Leadership

  • Organizational Chart

  • Member of the board

    Chairman
    Yang Xiaoming
    Director
    Liu Jingzhen
    Ma Ping
    Zhu Jingjin
    Wu Yonglin
    Lin Guang
    Liang Hongjun
    Staff Director
    Chen Jian
    Board secretary
    Li Xiangrong
         
  • Party committee members

    Party Secretary
    Zhu Jingjin
    Deputy Secretary of the Party Committee
    Yang Xiaoming
    Wu Yonglin
    Party committee
    Li Xiangrong
    Yang Huichuan
    Zhang Yuntao
    Zhou Song
         
  • Management Team

    President
    Wu Yonglin
    vice president
    Zhu Jingjin
    Li Xiangrong
    Zhang Yuntao
    financial director
    Hu Ligang
    Marketing director
    Zhang Yang
         
  • Disciplinary committee member

    Commission for Discipline Inspection
    Zhou Song
    Deputy Secretary of the Commission for Discipline Inspection
    Tang Ying
    Commissioner for Discipline Inspection
    Wang Xiaobing
    Li Xiuling
    Zhou Dongbo
         

Culture

  • Our Philosophy

    All for Health, Health for All

  • Our Values

    Love and Responsibility

  • Our Vision

    A standard-setting innovative biopharmaceutical company
    with global competitiveness and respect

Video Contributor, forerunner and innovator in the development of China’s biopharmaceutical industry

  • Gate: A Centennial Encounter
  • CHINA FORGES AHEAD ON THE ROAD OF INNOVATION: Figther Of Micro World

Milestones CNBG’s history represents the history of China’s biopharmaceutical industry

1919

National Epidemic Prevention Bureau (present-day Beijing Institute of Biological Products) was set up at the site of the former Divine Music Office in the Temple of Heaven in Beijing.The main responsibility was the prevention and control of infectious diseases in China, the bacteriological studies on infectious diseases and the production of various biological products.

1926

Qi Changqing from the National Epidemic Prevention Bureau extracted the smallpox virus from a patient to isolate attenuated strains and produced a smallpox vaccine which played a crucial role in eliminating smallpox in China.

1934-1958
兰州1934西北防疫处原址

Six key institutes of biological products were founded in Beijing, Lanzhou, Changchun, Shanghai, Wuhan, and Chengdu.

1942

National Epidemic Prevention Bureau isolated China’s first penicillin strain. The next year, it started research and development of penicillin, which marked the dawn of China’s history of antibiotic development. Around the same period, penicillin was produced in the liberated area.

1953

The Central People’s Government decided to put all public biological product institutes under the administration of the Ministry of Public Health (MPH). Soon, the MPH Biological Product Institute developed and produced the first yellow fever vaccine in the country, and Changchun Institute of Biological Products developed China’s first tick-borne encephalitis (TBE).

1955

The trachomatis research team headed by MPH Biological Product Institute Director Tang Feifan isolated the world’s first chlamydia trachomatis and named it “TE8,” winning glory for China in the international medical community.

1957

The measles research team headed by Tang Feifan isolated China’s first measles virus, which was named “M9.”

1960

China eliminated smallpox. The Department of Virology of the Chinese Academy of Medical Sciences joined Beijing Institute of Biological Products, Chengdu Institute of Biological Products, and the Institute of Food and Drug Control to develop China’s first live attenuated poliomyelitis vaccine and produce enough doses for 5 million people. More than 4 million children were vaccinated.

1978

China launched National Immunization Program, under which CNBG has been providing vaccines for the entire country.

1979

The World Health Organization (WHO) verified that China had eliminated smallpox in the 1960s. In December 1979 in Geneva, Zhang Yihao, director of Beijing Institute of Biological Products, signed a certificate of global eradication of smallpox as a member of the Global Commission for Certification of Smallpox Eradication. In May 1980, the 33rd World Health Assembly officially declared that the world and all its peoples had won freedom from smallpox.

1988

China’s immunization work was awarded a silver medal by the United Nations Children’s Fund (UNICEF). The Beijing Institute of Biological Products developed China’s first rubella vaccine.

1989

China Biological Products Corporation was established. In the same year, the Beijing Institute of Biological Products took the lead in introducing the technology for industrial production of recombinant yeast hepatitis B vaccine from the US-based Merck & Co.

1990

China’s first live attenuated poliomyelitis vaccine, jointly developed by Chengdu Institute of Biological Products and the Institute of Food and Drug Control, became the first in the world to be approved for production.

1997

China’s first microbial toxin product for clinical use, botulinum toxin type A for injection, which was independently developed by Lanzhou Institute of Biological Products, was officially approved for production and sales. This is the second botulinum toxin product to be approved for clinical treatment in the world, filling the blank in China.

1998

Initiated by Beijing Institute of Biological Products, Beijing Tiantan Biological Products Co., Ltd., was established. On May 18, the company was listed on Shanghai Stock Exchange.

The human diploid cell rubella live attenuated vaccine with independent intellectual property rights was approved by the Beijing Institute of Biological Products.

2001

The live oral rotavirus vaccine independently developed by Lanzhou Institute of Biological Products, was approved for production and sales and became one of the first two rotavirus vaccines marketed in the world.

2003

China Biological Products Corporation was renamed China National Biotec Group.

The Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine of Lanzhou Institute of Biological Products was approved for production, filling the gap of conjugate vaccine in the country.

2005

The National Development and Reform Commission approved the establishment of National Vaccine & Serum Institute Co., Ltd. by Beijing Institute of Biological Products, Beijing Tiantan Biological Products Co., Ltd. and the Institute of Virology. The project was included in the National High-Tech R&D Program of China (863 Program) as the only national base and service platform for the R&D, engineering and industrialization of new vaccines.

2006

The cell-free diphtheria conjugate vaccine production workshop, a national-level high-tech industrialization demonstration project, was built in the Huangjinqiao Production Base of Wuhan Institute of Biological Products Co., Ltd., laying the foundation for the traditional whole bacteria diphtheria vaccine to be gradually replaced by the cell-free diphtheria conjugate vaccine in our country.

20201228174345_89936.jpg

The 23-valent pneumococcal polysaccharide vaccine with independent intellectual property rights of Chengdu Institute of Biological Products Co., Ltd. was approved for production.

2009

The company was merged with and into Sinopharm to build a pharmaceutical and health industry platform of a central enterprise.

2010

After a further restructuring, China National Biotec Group Co., Ltd. was founded, affiliated to Sinopharm.

2011

The Expanded Program on Immunization was launched to eliminate measles, and wild poliovirus transmission was interrupted.

CNBG and Bill & Melinda Gates Foundation (BMGF) signed a Memorandum of Understanding on Strategic Partnership for Global Health.

2013

The live attenuated encephalitis B vaccine developed by CNBG became the first Chinese vaccine to pass WHO prequalification and reach the drug procurement list for UN agencies.

2014

National Vaccine & Serum Institute Co., Ltd. was established.

2018

Strategic Partnership for Global Health
BMGF CNBG Signing Ceremony of ? of Understanding

CNBG restructured its blood products businesses, and Beijing Tiantan Biological Products Co., Ltd. became a specialized platform in the segment.

2019
1575271167_1080x530.jpg

CNBG celebrated its 100th anniversary. The phase-1 clinical trial of class-1 new drug“11-valent HPV vaccine” was launched. Recombinant norovirus bivalent vaccine, another class-1 new drug, was approved by the National Medical Products Administration for clinical trials.

2020

CNBG responded quickly and made all-out efforts to fight the COVID-19 pandemic.

Home>About Us